Edward J Dulac III insider trades: Intellia Therapeutics (NTLA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Edward reports to the SEC
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 22, 2026 | NTLA | ↓ Sell | 8,111 | $11.25 | $91K | Direct | Jul 24, 2026 (2d) |
| Jul 2, 2026 | NTLA | ↓ Sell | 4,677 | $18.00 | $84K | Direct | Jul 6, 2026 (4d) |
| Jan 5, 2026 | NTLA | ↓ Sell | 6,379 | $9.21 | $59K | Direct | Jan 7, 2026 (2d) |
| Jul 23, 2025 | NTLA | ↓ Sell | 7,462 | $14.02 | $105K | Direct | Jul 25, 2025 (2d) |
| Mar 4, 2024 | FATE | ↓ Sell | 2,447 | $7.77 | $19K | Direct | Mar 5, 2024 (1d) |
| Jan 29, 2024 | FATE | ↓ Sell | 1,849 | $5.00 | $9K | Direct | Jan 30, 2024 (1d) |
| Jan 9, 2024 | FATE | ↓ Sell | 7,028 | $4.37 | $31K | Direct | Jan 10, 2024 (1d) |
| Jan 2, 2024 | FATE | ↓ Sell | 5,182 | $3.66 | $19K | Direct | Jan 3, 2024 (1d) |
| Dec 18, 2023 | FATE | ↓ Sell | 1,585 | $3.50 | $6K | Direct | Dec 19, 2023 (1d) |
| Aug 18, 2023 | FATE | ↓ Sell | 4,718 | $2.80 | $13K | Direct | Aug 21, 2023 (3d) |
| Jul 5, 2023 | FATE | ↓ Sell | 5,182 | $4.83 | $25K | Direct | Jul 6, 2023 (1d) |
| Jan 10, 2023 | FATE | ↓ Sell | 7,331 | $5.24 | $38K | Direct | Jan 11, 2023 (1d) |
| Aug 18, 2022 | FATE | ↓ Sell | 5,135 | $29.81 | $153K | Direct | Aug 19, 2022 (1d) |
| Jan 11, 2022 | FATE | ↓ Sell | 1,770 | $48.45 | $86K | Direct | Jan 13, 2022 (2d) |
| Dec 20, 2021 | FATE | ↓ Sell | 15,977 | $60.00 | $959K | Direct | Dec 21, 2021 (1d) |
| Sep 28, 2021 | FATE | ↓ Sell | 19,460 | $62.53 | $1.2M | Direct | Sep 30, 2021 (2d) |
| Aug 19, 2021 | FATE | ↓ Sell | 3,474 | $88.26 | $307K | Direct | Aug 20, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NTLA insiders
Open-market trades in the last 12 months
About Edward J Dulac III's insider trades
Edward J Dulac III is EVP, Chief Financial Officer at Intellia Therapeutics (NTLA). Since Aug 19, 2021, Edward has reported no open-market purchases and 17 sales worth $3.2M on SEC Form 4. In the last 12 months: 3 sales ($234K).
Their filings also include grants and awards (9 filings), option exercises (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NTLA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.